SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin enters into strategic partnership with Merck Serono

16 Sep 2014 Evaluate

Lupin has entered into a long term strategic partnership with Merck Serono, the Biopharmaceutical division of Merck. Lupin will support Merck Serono in the implementation of the company’s General Medicines portfolio expansion initiative in emerging markets thus addressing local needs for affordable, high-quality medicines. The agreement builds on an established working relationship between the two companies, and could add up to 20 new products to the current portfolio. The first launches are expected in 2016.

Through this partnership, Merck Serono will expand its overall portfolio in core therapeutic areas of Merck Serono’s General Medicine & Endocrinology franchise in selected countries in Latin America, Asia, Central Eastern Europe, and Africa.

The partnership covers major markets such as Brazil, Mexico, Indonesia, Philippines alongside several countries in Africa and Central Eastern Europe as well as other countries in emerging markets, focusing on cardiovascular and diabetes diseases. In Africa, medicines will also be supplied for additional therapeutic areas, reflecting local healthcare needs such as availability of antibiotics.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

 

Lupin Share Price

2398.70 2.20 (0.09%)
02-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.55
Dr. Reddys Labs. 1346.25
Cipla 1456.25
Zydus Lifesciences 1099.65
Lupin 2398.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: